Nonalcoholic Fatty Liver Disease and Mean Platelet Volume: A Systemic Review and Meta-analysis

Journal of Clinical Gastroenterology

Volumn 50, Issue 1, 2016, Pages 69-74

  Madan, Shivank A ^a   John, Febin ^b   Pitchumoni, Capecomorin S ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b SAINT PETER S UNIVERSITY HOSPITAL   (United States)

Author keywords

mean platelet volume; MPV; NAFLD; Nonalcoholic fatty liver disease

Indexed keywords

CINAHL; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; HUMAN; MEDLINE; NONALCOHOLIC FATTY LIVER; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTE VOLUME; BLOOD; CARDIOVASCULAR DISEASE; META ANALYSIS; METABOLIC SYNDROME X; METABOLISM; OBESITY; THROMBOCYTE;

BLOOD PLATELETS; CARDIOVASCULAR DISEASES; HUMANS; MEAN PLATELET VOLUME; METABOLIC SYNDROME X; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY;

EID: 84951742606     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000340     Document Type: Review

References (45)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221-1231.
2. Chalasani N, Younossi Z, Lavine J, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005-2023.
3. Salt W II. Nonalcoholic fatty liver disease (NAFLD): A comprehensive review. J Insur Med. 2003;36:27-41.
4. Targher G, Day C, Bonara E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363:1341-1350.
5. Marchesini G, Moscatiello S, Di Domizio S, et al. Obesityassociated liver disease. J Clin Endocrinol Metab. 2008;2008(suppl 1): S74-S80.
6. Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143:722-728.
7. Adiels M, Taskinen M-R, Borén J. Fatty liver, insulin resistance, and dyslipidemia. Curr Diab Rep. 2008;8:60-64.
8. Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. J Hepatol. 2010; 53:713-718.
9. Chu S, Becker R, Berger P, et al. Mean platelet volume as a predictor of cardiovascular risk: A systematic review and metaanalysis. J Thromb Haemost. 2010;8:148-156.
10. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest. 2005;115:3378-3384.
11. Meadows TA, Bhatt DL. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res. 2007;100:1261-1275.
12. Papanas N, Symeonidis G, Maltezos E, et al. Mean platelet volume in patients with type 2 diabetes mellitus. Platelets. 2004;15:475-478.
13. Nadar S, Blann A, Lip G. Platelet morphology and plasma indices of platelet activation in essential hypertension: Effects of amlodipine-based antihypertensive therapy. Ann Med. 2004;36: 552-557.
14. Pathansali R, Smith N, Bath P. Altered megakaryocyte-platelet haemostatic axis in hypercholesterolaemia. Platelets. 2001;12:292-297.
15. Avramakis G, Papadimitraki E, Papakonstandinou D, et al. Platelets and white blood cell subpopulations among patients with myocardial infarction and unstable angina. Platelets. 2007;18:16-23.
16. Trowbridge E, Slater D, Kishk Y, et al. Platelet production in myocardial infarction and sudden cardiac death. Thromb Haemost. 1984;52:167-171.
17. Khandekar M, Khurana A, Deshmukh S, et al. Platelet volume indices in patients with coronary artery disease and acute myocardial infarction: An Indian scenario. J Clin Pathol. 2006; 59:146-149.
18. Gasparyan AY, Ayvazyan L, Mikhailidis DP, et al. Mean platelet volume: A link between thrombosis and inflammation Curr Pharm Des. 2011;17:47-58.
19. O'malley T, Langhorne P, Elton R, et al. Platelet size in stroke patients. Stroke. 1995;26:995-999.
20. Ozhan H, Aydin M, Yazici M, et al. Mean platelet volume in patients with non-alcoholic fatty liver disease. Platelets. 2010; 21:29-32.
21. Celikbilek M, Gü rsoy S, Deniz K, et al. Mean platelet volume in biopsy-proven non-alcoholic fatty liver disease. Platelets. 2012;24:194-199.
22. Kilciler G, Genc H, Tapan S, et al. Mean platelet volume and its relationship with carotid atherosclerosis in subjects with non-alcoholic fatty liver disease. Ups J Med Sci. 2010;115: 253-259.
23. Shin W-Y, Jung D-H, Shim J-Y, et al. The association between non-alcoholic hepatic steatosis and mean platelet volume in an obese Korean population. Platelets. 2011;22:442-446.
24. Aktas G, Alcelik A, Tekce BK, et al. Mean platelet volume and red cell distribution width in Hepatosteatosis. Natl J Med Res. 2013;3:264-266.
25. Alkhouri N, Kistangari G, Campbell C, et al. Mean platelet volume as a marker of increased cardiovascular risk in patients with nonalcoholic steatohepatitis. Hepatology. 2012;55:331-331.
26. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529-536.
27. Das S, Mukherjee S, Vasudevan D, et al. Comparison of haematological parameters in patients with non-alcoholic fatty liver disease and alcoholic liver disease. Singapore Med J. 2011; 52:175-181.
28. Kocabay G, Karabay CY, Kalayci A, et al. Mean platelet volume in patients with non-alcoholic fatty liver disease: Is mean platelet volume ready as a surrogate marker Clin Chem Lab Med. 2014;52:e249-e252.
29. Targher G, Bertolini L, Poli F, et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes. 2005;54:3541-3546.
30. Targher G, Bertolini L, Rodella S, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes care. 2007;30:2119-2121.
31. Haring R, Wallaschofski H, Nauck M, et al. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology. 2009;50:1403-1411.
32. Rafiq N, Bai C, Fang Y, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 2009;7:234-238.
33. Bieghs V, Rensen PC, Hofker MH, et al. NASH and atherosclerosis are two aspects of a shared disease: Central role for macrophages. Atherosclerosis. 2012;220:287-293.
34. Gaggini M, Morelli M, Buzzigoli E, et al. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013;5:1544-1560.
35. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363:1341-1350.
36. Tilg H, Moschen AR. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metabol. 2008;19:371-379.
37. Stefan N, Kantartzis K, Haring H-U. Causes and metabolic consequences of fatty liver. Endocr Rev. 2008;29:939-960.
38. Varol E, Akcay S, Ozaydin M, et al. Mean platelet volume is associated with insulin resistance in non-obese, non-diabetic patients with coronary artery disease. J Cardiol. 2010;56: 154-158.
39. Zuberi B, Akhtar N, Afsar S. Comparison of mean platelet volume in patients with diabetes mellitus, impaired fasting glucose and non-diabetic subjects. Singapore Med J. 2008;49:114-116.
40. Dav G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357:2482-2494.
41. Fitzgerald DJ, Roy L, Catella F, et al. Platelet activation in unstable coronary disease. N Engl J Med. 1986;315:983-989.
42. Bath P, Butterworth R. Platelet size: Measurement, physiology and vascular disease. Blood Coagul Fibrinolysis. 1996;7: 157-161.
43. Butterworth R. The relationship between mean platelet volume, stroke subtype and clinical outcome. Platelets. 1998; 9:359-364.
44. Greisenegger S, Endler G, Hsieh K, et al. Is elevated mean platelet volume associated with a worse outcome in patients with acute ischemic cerebrovascular events Stroke. 2004;35: 1688-1691.
45. Arikanoglu A, Yucel Y, Acar A, et al. The relationship of the mean platelet volume and C-reactive protein levels with mortality in ischemic stroke patients. Eur Rev Med Pharmacol Sci. 2013;17:1774-1777.